Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ventricular Tachycardia - Overview
Ventricular Tachycardia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Ventricular Tachycardia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ventricular Tachycardia - Companies Involved in Therapeutics Development
Academic Pharmaceuticals Inc
Armgo Pharma Inc
BioStem Technologies Inc
Elex Biotech LLC
Espero BioPharma Inc
GEXVal Inc
Gilead Sciences Inc
InCarda Therapeutics Inc
Milestone Pharmaceuticals Inc
Vivasc Therapeutics Inc
Ventricular Tachycardia - Drug Profiles
amiodarone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BSEM-125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budiodarone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etripamil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
flecainide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-967 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Cardiomyopathies and Catecholaminergic Polymorphic Ventricular Tachycardia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Ryanodine Receptor 2 for Catecholaminergic Polymorphic Ventricular Tachycardia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit FKBP1A for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
soestelol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ventricular Tachycardia - Dormant Projects
Ventricular Tachycardia - Discontinued Products
Ventricular Tachycardia - Product Development Milestones
Featured News & Press Releases
Mar 23, 2020: Milestone Pharmaceuticals announces topline results from first-of-its-kind phase 3 NODE-301 trial of etripamil for at-home acute PSVT treatment
Oct 03, 2019: Milestone Pharmaceuticals announces first patient enrolled in NODE-303 open-label safety study of Etripamil in PSVT
May 21, 2019: Milestone Pharmaceuticals presents studies on the economic impacts of PSVT at the ISPOR 2019 Annual Meeting
Apr 16, 2019: Milestone Pharmaceuticals appoints Paul Edick chairman of its board of directors
Apr 16, 2019: Milestone Pharmaceuticals appoints Paul Edick chairman of its board of directors
Aug 08, 2018: Milestone Pharmaceuticals announces first patient randomized in the phase 3 NODE-301 clinical trial evaluating Etripamil for termition of paroxysmal supraventricular tachycardia (PSVT) episodes
May 11, 2017: Milestone Pharmaceuticals Announces Etripamil Phase 2 Clinical Program Success for the Treatment of Paroxysmal Supraventricular Tachycardia
Apr 12, 2017: Milestone Pharmaceuticals to Present Etripamil Phase 2 Data at the Heart Rhythm Society’s 38th Annual Scientific Sessions
Mar 07, 2017: Milestone Pharmaceuticals Announces Appointment of Joseph G. Oliveto as Chief Executive Officer
Aug 31, 2016: InCarda Therapeutics Initiates Enrollment of Phase 1 Clinical Trial of Inhaled Flecainide for the Treatment of Cardiac Arrhythmias
Jan 25, 2016: Milestone Pharmaceuticals Announces USAN Approval of Generic me "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia
Jan 12, 2015: Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phase 2 IND
Nov 24, 2014: Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients
Oct 28, 2013: Milestone Pharmaceuticals Initiates a Phase 1 Clinical Trial with MSP-2017
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Ventricular Tachycardia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development for Ventricular Tachycardia, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Ventricular Tachycardia - Pipeline by Academic Pharmaceuticals Inc, H1 2020
Ventricular Tachycardia - Pipeline by Armgo Pharma Inc, H1 2020
Ventricular Tachycardia - Pipeline by BioStem Technologies Inc, H1 2020
Ventricular Tachycardia - Pipeline by Elex Biotech LLC, H1 2020
Ventricular Tachycardia - Pipeline by Espero BioPharma Inc, H1 2020
Ventricular Tachycardia - Pipeline by GEXVal Inc, H1 2020
Ventricular Tachycardia - Pipeline by Gilead Sciences Inc, H1 2020
Ventricular Tachycardia - Pipeline by InCarda Therapeutics Inc, H1 2020
Ventricular Tachycardia - Pipeline by Milestone Pharmaceuticals Inc, H1 2020
Ventricular Tachycardia - Pipeline by Vivasc Therapeutics Inc, H1 2020
Ventricular Tachycardia - Dormant Projects, H1 2020
Ventricular Tachycardia - Discontinued Products, H1 2020